Penile erection is a complex physiological process in which the regulation of penile hemodynamics depends on signal input from central and peripheral nervous systems, and on the balance and interplay between several local physiological mediators (neurotransmitters, vasoactive agents and endocrine factors). A role for the sympathetic nervous system in attaining or maintaining penile¯accidity and detumescence is well recognized. However, the exact mechanisms of alpha-adrenergic receptor mediated erectile function remain poorly de®ned. The objective of this review is to summarize data presented in the literature and from our laboratory on alpha-adrenergic receptors, and to discuss the conceptual framework by which the alphaadrenergic receptor pathway modulates penile corpus cavernosum smooth muscle contractility. We will integrate the current state of knowledge of penile erection into one framework encompassing the biochemical and physiological pathways responsible for trabecular smooth muscle relaxation (erection) and contraction (detumescence). We will focus our discussion on local control mechanisms of alpha-adrenergic receptors and explore the following topics: (1) functional activity of alpha-1 and alpha-2 adrenergic receptors in the physiology of human penile erection; (2) identi®cation, classi®cation and characterization of alpha-1 and alpha-2 adrenergic receptor subtypes in human penile erectile tissue; (3) molecular mechanism of action of alpha-1 and alpha-2 adrenergic receptors in human penile erectile tissue; (4) blockade of alpha-1 and alpha-2 adrenergic receptor action by selective and non-selective alpha-1 and alpha-2 adrenergic receptor antagonists (blockers); (5) physiologic (functional) antagonism of alpha-1 and alpha-2 adrenergic receptor activity by vasodilators mediating smooth muscle relaxation; and (6) key areas of consensus, as well as critical gaps in the existing scienti®c knowledge concerning the rationale and the potential use of alpha-blockers in erectile function.
Introduction
Penile erectile function is a complex physiological process involving integration of multiple biochemical signals elicited in response to several neurotransmitters and vasoactive agents involved in regulation of penile erection and¯accidity. 1±5 Physiological and biochemical studies over the past three decades have demonstrated that corpus cavernosum trabecular smooth muscle is an important structure in the penis and contributes to control of penile erection and¯accidity. 6±8 Adrenergic nerves, via release of the neurotransmitter norepinephrine and synthesis and release of vasoconstrictor substances from the endothelium such as endothelins and contractile prostaglandins, mediate local control of trabecular smooth muscle contractility. In thē accid penis, the smooth muscle of the trabeculae and penile cavernosal arteries is maintained in the contracted state by contractile agonists. These chemical messengers interact with speci®c membrane receptors and ion channels modulating intracellular calcium andaor altering calcium sensitivity to contractile proteins producing smooth muscle contraction. 2, 9 One of the key pathways modulating penilē accidity is the release of norepinephrine from the adrenergic nerves and binding to post-junctional alpha-1 and alpha-2 adrenergic receptors localized to the smooth muscle of cavernosal arteries and trabeculae. 1,2,9±18 This reaction causes activation of G-protein coupled alpha-adrenergic receptors and activation of several signal transduction pathways leading to smooth muscle contraction. Upon sexual stimulation, activation of non-adrenergic non-cholinergic nerves results in the synthesis and release of nitric oxide (NO), among other substances, which diffuses into the arterial and trabecular smooth muscle of corpus cavernosum. 19±22 NO interacts with guanylyl cyclase resulting in its activation, increasing cyclic guanosine monophosphate (cGMP) synthesis. The NOacGMP signal transduction pathways, integrates into the overall regulation of myosin light chain kinase, and myosin light chain phosphatase and intracellular calcium concentration. The net effect is reduced intracellular calcium, via subcellular sequestration into intracellular calcium stores or by extrusion, reduced smooth muscle tone and enhanced smooth muscle relaxation and penile erection. 23 Several physiological and biochemical mechanisms involved in the integration and ®ne regulation of multiple signal transduction pathways maintaining smooth muscle contractility have been described. 1±5,24 These mechanisms are critical for penile erection. Erectile dysfunction may be a result of an imbalance in the integration of biochemical messengers and signals in this complex physiological process. Thus, biochemical changes in neurotransmitter synthesis or release, receptor expression, cellular distribution or function, andaor modi®cations in any of the multiple downstream events along the signal transduction cascade responsible for vasoconstriction over vasodilation may result in erectile dysfunction. 3, 4, 24 Thus, fundamental knowledge of the biochemical and physiological mechanisms of neurotransmitters and vasoactive substances and their receptor function modulating smooth muscle contraction and relaxation is critical to our understanding of erectile function, and for the development of new pharmacotherapeutic strategies to manage patients with erectile dysfunction.
Currently, the ®rst step in management of male erectile dysfunction involves the use of oral pharmacological agents, vacuum constrictive devices or sex therapy. Research on nitric oxide mediated relaxation of trabecular smooth muscle and enhancement of penile erection has led to the development of a new, safe and effective oral agent, sildena®l citrate (Viagra TM ) for treatment of male erectile dysfunction.25 À 27 Since alpha-adrenergic receptors play a critical role in initiating andaor maintaining penile¯accidity, understanding the mechanism of the alpha adrenergic receptor pathway in modulating erectile function may provide new insights into the use of alpha adrenergic receptor antagonists (blockers), alone or in combination with other agents, in the treatment of erectile dysfunction.
Role of alpha-1 and alpha-2 adrenergic receptors in human penile erectile function
The alpha-adrenergic neuroeffector system plays a critical physiological role in erectile function.2Y 9Y 10Y 12Y 14Y 15Y 28 À 31 Evidence derived from in vitro and in vivo studies has indicated that adrenergic nerves, a major source of physiologically active norepinephrine, innervate human penile corpus cavernosum. 2, 32, 33 Release of norepinephrine from the sympathetic nerve ®bers of the human corpus cavernosum is modulated by presynaptic alpha-2 adrenergic receptors and cholinergic nerves via prejunctional muscarinic acetylcholine receptors (see Figure 1) . 6, 12, 34, 35 Detailed analyses of these interactions are provided in the accompanying article by The af®nity of the receptor for prazosin was greater than that for yohimbine, suggesting predominance of alpha-1 adrenergic receptors over alpha-2 adrenergic receptors in human erectile tissue. 13, 15 These studies demonstrated the important role of alpha-1 adrenergic receptors in erectile function.
Classi®cation of alpha-adrenergic receptor subtypes in human corpus cavernosum
Classi®cation and nomenclature of the alpha 1 and alpha 2 adrenergic receptor subtypes has been recently reported. 43±49 The alpha-1 adrenergic receptors were classi®ed into alpha-1a (formerly alpha-1c), alpha-1b and alpha-1d (formerly alpha1a) based on cDNA sequences and agonist and antagonists binding characteristics. 46 ,50±51 Capital letters denote the pharmacological classi®cation and lower case letters denote the cloned receptor subtypes (Tables 1±3) . Throughout this review we will adhere to this convention of classi®cation and nomenclature. Pharmacological and ligand binding studies with selective agonists and antagonists lead to classi®ca- 46, 47) . A summary of the selective agonists and antagonists for these three subtypes is shown in Table 2 . A fourth receptor subtype referred to as alpha-1L (low af®nity to prazosin) has been reported (reviewed in ref. 44 ). However, the cDNA for this subtype is yet to be described. Because of insuf®-cient molecular and pharmacological information on this subtype it will not be discussed further in this review.
Biochemical studies employing pharmacological agents clearly suggested that, while discrimination between alpha-1 and alpha-2 adrenergic receptors is possible, it is dif®cult to unequivocally distinguish the alpha-1 or alpha-2 adrenergic receptor subtypes in human corpus cavernosum using a single biochemical or pharmacological approach. Alpha adrenergic selective agonists and antagonists bind to the various receptor subtypes over a wide range of concentrations with varying af®nities and selectivities but little de®ned speci®city. 16±18,51,54 This lack of receptor subtype`speci®c' ligands for the alpha 1 adrenergic receptor has hampered the unequivocal assignment of the receptor subtypes responsible for the contractile response to norepinephrine. The availability of speci®c molecular biological probes to identify and characterize the various subtypes, together with biochemical approaches had facilitated identi®cation of these subtypes. 50 However, assigning biological functions for each of these subtypes and determining the relative contribution to the contractile response by these subtypes is yet to be fully determined in human corpus cavernosum.
Identi®cation of alpha-1 adrenergic receptor subtypes in human penile corpus cavernosum
Several pharmacological and biochemical studies have con®rmed the presence of alpha-adrenergic receptors in penile tissue. However, these studies did not identify the nature of receptor subtypes expressed in human penile corpus cavernosum. In a series of studies, we demonstrated that human erectile corpus cavernosum tissue expresses mRNA transcripts for alpha-1a, alpha-1b and alpha-1d adrenergic receptor subtypes (Figure 2A ). 16 The abundance of mRNA transcripts for these subtypes in human corpus cavernosum, suggested that alpha1a and alpha-1d adrenergic receptors are predominant 56 These studies document the expression of three alpha-1 adrenergic receptors in erectile tissue. Based on pharmacological studies, Tong and Cheng 57 have suggested that the alpha-1A receptor subtype was responsible for inducing contraction in the rat corpus cavernosum. In contrast, Furukawa et al 58 have suggested that the alpha-1B adrenergic receptor subtype mediates the contractile response in the rabbit corpus cavernosum. This conclusion was based on pharmacological studies using WB 4101, 5-methylurapidil, chloroethylchlonidine, oxymetazoline and tamsulosin. Although it is becoming clear that at least three alpha-1 adrenergic receptor subtypes are expressed in erectile tissue, their functional and physiological signi®cance remains unknown. Several questions remain to be answered. What role does each receptor subtype play in mediating smooth muscle contractility? What is the relative contribution of each of these receptor subtypes to the signalling pathway modulating intracellular calcium levels? How does the selectivity of these receptor subtypes to various alpha antagonists determine the potential usefulness of targeted alpha-blockers as drugs for therapeutic purposes? Clearly, investigation of the role of the various subtypes in regulating corpus cavernosum function is warranted.
Identi®cation and characterization of alpha-2 adrenergic receptor subtypes in penile corpus cavernosum Pharmacological studies in human corpus cavernosum tissue have suggested the expression of postjunctional alpha-2 adrenergic receptors. However, it was concluded that alpha-2 adrenergic receptors do not contribute signi®cantly to the contractile activity of trabecular smooth muscle. 2, 15, 31 This conclusion is based on the observations that the constrictor response to electrical ®eld stimulation is blocked mainly with alpha-1 adrenergic receptor antagonists but not with alpha-2 adrenergic receptor antagonists (Tables 2 and 3) . 15, 31 Since high concentrations of antagonists were used in these studies, the selectivity of the antagonists for alpha-1 and alpha-2 adrenergic receptors is compromised at high drug concentrations due to lack of speci®city. 46, 51, 54 Therefore, the assignment of a speci®c functional activity to a speci®c receptor class or subclass based only on pharmacological analyses is suggestive, at best. Further, although yohimbine and rauwolscine (highly selective alpha-2 adrenergic receptor anta- Figure 4 Proposed molecular mechanism of action of alpha-1 adrenergic receptors in penile corpus cavernosum smooth muscle cells.
Alpha adrenergic receptor blockade in erectile dysfunction A Traish et al gonists) were shown to inhibit norepinephrine-induced contraction in corpus cavernosum, no physiological role was assigned for alpha-2 adrenergic receptors in human penile erectile tissue. 15, 28, 31, 59 In the absence of detailed biochemical and molecular biological analyses of the alpha-2 adrenergic receptors expressed in corpus cavernosum tissue and their functional activities, it remains unclear if alpha-2 adrenergic receptors are expressed in the corpus cavernosum tissue and if these receptors are physiologically functional.
We have demonstrated mRNA expression for alpha-2a, alpha-2b and the alpha-2c adrenergic receptor subtypes in human corpus cavernosum tissue ( Figure 2B ). 17 17 Physiological studies with selective alpha-2 antagonists have clearly supported the expression of biochemically functional alpha-2 adrenergic receptors. 11, 17 The data from the molecular biology, biochemistry and physiological studies suggest that human corpus cavernosum expresses physiological functional alpha-2 adrenergic receptors.
Functional (physiological) studies of alpha-1 and alpha-2 adrenergic receptors in erectile tissue
The blockade of electric ®eld stimulation inducedcontraction by prazosin in human corpus cavernosum supports a role for functional post-junctional alpha-1 adrenergic receptors in penile erectile tissue. 15 Norepinephrine causes dose-dependent contraction in human corpus cavernosum smooth muscle. 2, 12, 15, 16, 18, 31, 60 Norepinephrine dose response curve was shifted to the right with increasing concentrations of the alpha-1Aa1D adrenergic receptors antagonist WB4101 and the alpha-1B receptor antagonist chloroethylchlonidine. 60 Phentolamine, an alpha-1 and alpha-2 antagonist, shifted the phenylephrine contractile dose-response curve to the right. 18 Phentolamine produced dose-dependent relaxation response in corpus cavernosum tissue strips pre-contracted with norepinephrine, oxymetazoline or phenylephrine. Similar relaxation responses, in a dose-dependent fashion, were obtained with doxazosin, terazosin, prazosin and tamsulosin (N. Kim, unpublished data). These observations strongly suggest that alpha-1 adrenergic receptor subtypes modulate trabecular smooth muscle contractility in human erectile tissue.
Functional studies with human and rabbit erectile tissue using UK14304, a selective alpha-2 adrenergic agonist demonstrated dose-dependent contractions. 11, 17 UK14304-dose response curve was shifted to the right by selective alpha-2 adrenergic receptor antagonists, rauwolscine and delequamine (RS15385-197). 11, 17 Furthermore, phentolamine caused a dose-dependent relaxation of corpus cavernosum tissue strips pre-contracted with UK14304. 18 UK14304 inhibited PGE1 and forskolin induced-cAMP synthesis in cultured human and rabbit corpus cavernosum smooth muscle cells. 11, 17 The UK14304 mediated inhibition of forskolin-induced cAMP synthesis and the shift of the contractile dose response curve of UK14304 by delequamine (RS15385-197) suggest that postjunctional alpha-2 adrenergic receptors in human penile erectile tissue are biochemically and physiologically functional.
The alpha-1 adrenergic receptor agonists elicit greater contractile responses than those obtained with the alpha-2 adrenergic receptor agonists. 11 This suggests that alpha 1 adrenergic receptors contribute more to the contractility of human corpus cavernosum smooth muscle. 2,12,14±16,18,31,60 This physiological difference may be attributed to a lower density of the alpha-2 adrenergic receptors on penile smooth muscle. Also, post-synaptic alpha-2 adrenergic receptors may be localized on the smooth muscle distal to the adrenergic nerve terminals. Furthermore, the distribution of alpha-2 adrenergic receptors on the different cell types of penile erectile tissue may be different from that of the alpha-1 adrenergic receptors.
Molecular mechanism of alpha-1 adrenergic receptors action in erectile tissue corpus cavernosum
Norepinephrine released from the adrenergic nerve terminals binds to alpha-1 adrenergic receptor subtypes localized on the smooth muscle of corpus cavernosum and cavernosal arteries. This binding reaction results in conformational changes in the 7-transmembrane receptor molecule leading to activation of the heterotrimeric Gqa11 protein and increased rate of GDP dissociation (Figures 3 and  4) . The exchange of GDP with GTP in the binding site of the a-subunit of the G-protein results in its dissociation into alpha and betaagamma subunits. The Gaaq subunit interacts with phospholipase C b1 and stimulates its activity producing hydrolysis of phosphatidylinositol 4,5-bis-phosphate (PIP2) into 1,4,5-inositol trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 diffuses into the cytoplasm where it binds to a speci®c receptor on the sarcoplasmic 61 produces smooth muscle relaxation. It is not known if contractile agonists inhibit MLCP activity in addition to activating the MLCK, and bring about contraction. In addition to these primary mechanisms other mechanisms are proposed in which phosphorylation of MLC 20 takes place in the absence of increased intracellular Ca 2 -calmodulin. 62 The altered balance between the activities of Ca 2 -independent kinase and inhibition of phosphatase increases MLC 20 phosphorylation causing contraction in the absence of increased intracellular Ca 2 ( Figure 4 ). Other mechanisms of smooth muscle contraction have implicated G protein activating Ca 2 -sensitizing cascade via monomeric GTpase RhoA. The downstream Ca sensitizing effector of RhoA is mediated by Rho kinase, which phosphorylates the regulatory subunit of myosin light chain phosphatase and inhibits its catalytic activity. 63 Molecular mechanism of action of alpha-2 adrenergic receptors in erectile tissue corpus cavernosum
The mechanism of alpha-2 adrenergic receptor action in human corpus cavernosum is yet to be fully understood. Studies in other vascular systems have shown that activation of the alpha-2 adrenergic receptor inhibits adenylate cyclase activity via heterotrimeric G i -proteins (reviewed in ref. 45 ) and reduce intracellular cAMP. We have demonstrated that UK14304 decreased the forskolin or PGE1-induced cAMP synthesis in cultured human and rabbit corpus cavernosum smooth muscle cells ( Figure 5 ). 11, 17 This reduction in cAMP synthesis leads to reduced protein kinase A (PKA) activation and increased intracellular calcium or calciuma 45 These receptors are also implicated in activation of phospholipase C, phospholipase D, potassium channels and NaaH exchange. 45 Whether these mechanisms are integrated in increasing corpus cavernosum smooth muscle tone is unknown at present. Nevertheless, the demonstration of functional post-junctional alpha-2 adrenergic receptor in human and rabbit corpus cavernosum suggests that these receptors contribute to the contractility of corpus cavernosum smooth muscle. 11, 17 Modulation of agonist induced contraction of smooth muscle by the endothelium has been reported in other vascular beds. 64 In aortic rings, concentration±response curves produced by norepinephrine (NE) are displaced to the left in the absence of the endothelium, without a change in the magnitude of the maximal response. 64 This suggests that NE-mediated contraction is antagonized by endothelium-derived vasoactive substances, at the receptor level andaor at a step in the biochemical pathway leading to contraction. Contractile agonists may modulate smooth muscle relaxation by binding to a speci®c receptor on the endothelium and releasing vasorelaxatroy substances. For instance, methoxamine, phenylephrine, clonidine and B-HT 920 (agonists that stimulate contractility in smooth muscle) increased intracellular cGMP only in the presence but not in the absence of the endothelium, suggesting release of nitric oxide (NO), presumably via alpha-2 adrenergic receptors on the endothelium. 65 
Alpha adrenergic receptor blockade in erectile dysfunction
A Traish et al alpha-1 and alpha-2 adrenergic receptors activation is signi®cantly modulated by endothelium in vascular beds. Thus, it remains to be determined if human corpus cavernosum endothelium modulates smooth muscle contractility via activation of NO by binding of NE to alpha-2 adrenergic receptors on the endothelium.
Blockade of alpha-1 and alpha-2 adrenergic receptor activity by selective and non-selective alpha-1 and -2 receptor antagonists
Blockade of the sympathetic neurotransmitter norepinephrine and the neurohormone epinephrine actions, at the alpha-adrenergic receptors, has been the basis of drug therapy in urogenital disorders. 66 As summarized in Figure 6 , competitive inhibition or displacement of norepinephrine binding to the alpha-receptor by the antagonist inhibits receptor activation and, in turn, attenuates the signal transduction pathway. Alpha-adrenergic blockade was ®rst used in the early 1980s in treatment of erectile dysfunction. 36, 37, 39 Nevertheless, this approach has yet to be fully exploited, in part, because of limited understanding of the mechanism of adrenergic receptor function in erectile tissue. In this section, we summarize studies from our laboratory and work by others on the functional antagonism of alphaadrenergic receptors by selective antagonists in erectile tissue. Injection of phenoxybenzamine has 36 Further studies utilizing the alpha-blocker, phentolamine as an injectable agent produced mixed results. 37 These observations suggested potential usefulness of alpha blockade in treatment of erectile dysfunction, however, basic science and clinical research must be carried out to investigate this fully. Buccal and oral phentolamine produced satisfactory erections for penetration in impotent men. 42 Oral phentolamine, similar to intracavernosal injection of phentolamine, produced penile tumescence and enhanced responsiveness to sexual stimulation which in turn produced rigidity. 39 Phentolamine (Regitine TM ) has been used alone and in combination with a variety of vasodilators (such as papaverine and PGE1) as an intracavernosal injectable treatment for erectile dysfunction (reviewed in ref. 67 ). Combinations of vasoactive intestinal peptide (VIP) and phentolamine have been tested in pilot studies as intracavernosal therapeutics. 68, 69 In a recent clinical trial, Becker et al. 70 evaluated the ef®cacy of oral phentolamine mesylate in treatment of men with erectile dysfunction. The authors concluded that oral phentolamine may be of bene®t for the treatment of erectile dysfunction. Unpublished studies have demonstrated safety and ef®cacy of phentolamine in treatment of erectile dysfunction (I. Goldstein, personal communication). Although phentolamine has been used as an intracavernosal and oral agent in treatment of erectile dysfunction (reviewed in refs 27, 67), a detailed analysis of its mechanism of action in erectile tissue was not reported. Several classes of alpha adrenergic blockers have been synthesized and screened for their potential usefulness in inhibiting receptor activity (reviewed in refs 46, 51) . Different alpha-adrenergic receptor blockers possess various structural determinants that confer selectivity, af®nity and ef®cacy ( Figure 7) . Thus, it is expected that different alphablockers will have different physiological responses in vivo. Below is a summary of the action of several alpha-blockers, which have been employed, in physiological studies and in clinical trials in erectile dysfunction. 17 These data clearly indicate that phentolamine is an alpha-1 and alpha-2 antagonist in penile smooth muscle.
Phentolamine mesylate, at concentrations ranging from 1nM to 10mM, displaced the phenylephrine contractile dose-response curve to the right in organ bath studies with corpus cavernosum strips. 18 In human and rabbit corpus cavernosum erectile tissues, phentolamine caused dose-dependent relaxation in tissue strips pre-contracted with 3 mM phenylephrine. The half-maximal relaxation response (EC 50 ) occurred at 10±30nM phentolamine and the maximal relaxation response was reached at 1 mM. Phentolamine caused dose-dependent relaxation in strips pre-contacted with 1 mM phenylephrine, 5 mM norepinephrine or 1 mM oxymetazoline. Phentolamine mesylate, in concentrations ranging from 10 nM to 1 mM, also displaced the UK14304 contractile response to the right. Phentolamine caused dose-dependent relaxation in strips precontracted with 3 or 10 mM UK14304. In human erectile tissues pre-contracted with 3 mM UK14304, the half-maximal relaxation response (EC 50 ) occurred at 30±50 nM phentolamine, and the maximal relaxation response occurred at 1mM. These results suggest that phentolamine mesylate is an effective alpha-1 and alpha-2 antagonist and inhibits norepinephrine mediated responses in vitro.
In rabbit corpus cavernosum strips pre-contracted with 80 mM KCl or 30 nM endothelin-1, phentolamine mesylate caused concentration-dependent relaxation. 18 Since the mechanisms of contraction induced by KCl or endothelin-1 are not mediated by alpha adrenergic receptors, an additional nonadrenergic mechanism for phentolamine-induced corpus cavernosum relaxation was suspected. Phentolamine mesylate did not inhibit the binding of the L-type calcium channel-blocker, [ 3 H]PN 200-110, a nitripidine analogue, in human corpus cavernosum membranes, suggesting that phentolamine may not be acting on this type of calcium channel (N. Kim and A. Traish, unpublished data). Phentolamine mesylateinduced relaxation in corpus cavernosum smooth muscle pre-contracted with 80 mM KCl and this response was shifted to the right in the presence of the reversible nitric oxide synthase inhibitor, L nitroarginine (LNNA, 30mM). Similarly, the relaxation response of corpus cavernosum strips pre-contracted with 30nM endothelin-1 was reduced in the presence of LNNA (30 mM). These observations suggest that phentolamine, by blocking the action of alpha-1 and alpha-2 activity by endogenously released norepinephrine, enhances the effectiveness of the NO released constitutively by the corpus cavernosum endothelium producing relaxation of tissue precontracted with K or with endothelins. (Minipress  TM ) is an alpha-1A, -1B and -1D selective antagonist. 51 While introduced primarily as an antihypertensive agent, 71 it has been used orally to treat psychogenic erectile dysfunction. 72 Prazosin has also been used, in combination with alprostadil (PGE1), as an intraurethral agent for treatment of erectile dysfunction. 73 Although prazosin is thought to be alpha-1 selective, it does cross-react with alpha-2 adrenergic receptors, as suggested from biochemical binding studies.
Alpha-1 selective antagonists Prazosin hydrochloride
Doxazosin mesylate (Cardura TM ) is an alpha-1A and-1D selective blocker and possesses no af®nity for alpha-2 adrenergic receptors.51 Doxazosin has been utilized clinically in the treatment of hypertension and benign prostatic hyperplasia. 74 , 75 Kaplan et al 76 showed that oral doxazosin increased the ef®cacy of alprostadil injected intracavernosally. It was noted that patients taking doxazosin experience lower incidence of erectile dysfunction (2.8%) than other hypotensive agents. The authors concluded that their data do not support the use of doxazosin alone in the management of erectile dysfunction. 76 However, it is interesting to note that in the Treatment of Mild Hypertension Study, patients taking doxazosin reported a lower incidence of erectile dysfunction. 77 Terazosin hydrochloride (Hytrin TM ) is an alpha-1 adrenergic selective antagonist with high af®nity for alpha-1D receptor subtype. 78 It is clinically utilized for the treatment of benign prostatic hyperplasia but not hypertension. 79 It has been reported in a single case study that terazosin caused prolonged erection in a spinal cord injury patient. 80 Tamsulosin hydrochloride (Flomax  TM ) is an alpha-1 adrenergic receptor blocker, which possesses higher af®nity for alpha-1A and alpha-1D than alpha-1B. 78, 81, 82 A detailed pharmacological analysis of interaction of tamsulosin with cloned alpha-1 adrenergic receptor subtypes revealed that tamsulosin is a high af®nity antagonist with selectivity for alpha-1D ! alpha-1A b alpha-1B. 81, 82 Tamsulosin is clinically used for the treatment of benign prostatic hyperplasia, but not for the treatment of hypertension. 83 Trazodone hydrochloride (Desyrel TM ) is an oral serotonergic antidepressant which was noted to improve erectile function in impotent men and cause prolonged erections and priapism in potent men. 40, 41 Injection of trazodone intracavenosally in the rabbit penis produced full penile erection in 76±84% of animals. Injection of trazodone into volunteers produced tumescence but not full penile erection. It was concluded that trazodone acts as an alpha adrenergic receptor antagonist in enhancing penile erection but not initiating penile erection. 40 Intracavernosal trazadone was found to be associated with priapism in a canine model. 38 Saenz de Tejada et al reported on the pathophysiology of prolonged erections associated with trazodone use. 41 Trazodone signi®cantly improved nocturnal penile tumescence. Trazadone displaced NE-induced dose dependent contractile response curve to the right and caused dose dependent relaxation of tissue strips pre-contracted with NE. Trazodone also reduced the contractile response to electrical ®eld stimulation. 41 These observations suggest that trazodone hydrochloride acts peripherally via a mechanism mimicking alpha blocking properties. 38, 40, 41 It should be noted that metabolites of trazadone can activate hydroxytryptamine receptors (HT1c) in the spinal cord, and these metabolites are believed to contribute to the erectogenic effect of this drug (reviewed in ref. 27) . A recent clinical trial showed some ef®cacy of trazadone in treatment of psychogenic erectile dysfunction. 84 Alpha-2 selective antagonists Yohimbine is an indole alkaloid that has been widely used for treatment of psychogenic impotence. 85±88 Yohimbine's aphrodisiac activity may be mediated through a combination of central nervous system effects and peripheral effects including the blockade of pre-synaptic alpha-2 adrenergic receptors, resulting in enhanced blood¯ow and decreased blood out¯ow from erectile tissue and enhanced libido. Although yohimbine, a selective alpha-2 adrenergic receptor antagonist, has been widely used in treatments of psychogenic male erectile dysfunction, 86±89 with some success; its exact mechanism of action remains unknown. A recent study has shown that yohimbine is ineffective in treatment of organic erectile dysfunction. 90 Inhibition of presynaptic alpha-2 adrenergic receptors regulate the exocytotic norepinephrine release (Figure 1) . 15, 88, 91 This would suggest increased smooth muscle contractility due to increased catecholamine release. However, yohimbine may facilitate trabecular smooth muscle relaxation by binding to post-junctional alpha-2 adrenergic receptors on the smooth muscle or on the cavernosal arteries, and inhibiting contraction. A possible mechanism of yohimbine action in regulation of erectile function, especially in the patients with psychogenic erectile dysfunction, is a combined effect on the central nervous system by increased systemic blood pressure and peripheral effects at penile arterial and trabecular smooth muscle by attenuating contraction.
Delequamine is a selective alpha-2 adrenergic receptor antagonist which was shown to shift the UK 14,304 dose±response curve to the right in human corpus cavernosum 17 and in rabbit corpus cavernosum. 11 In an elegant and detailed study, Munoz et al 92, 93 demonstrated that delequamine when administered to healthy volunteers, had several effects. An increase in spontaneous erection, increased subjective rating of sexual arousal, increased duration of erectile response to erotic stimuli and increases in systolic blood pressure and heart rate before and during erotic stimulation. It was noted that the adverse effects of the drug were minimal. In a subsequent study, Munoz et al 92, 93 further investigated the effects of delequamine in young and old men with suspected psychogenic erectile dysfunction. It was suggested that delequamine may reverse the inhibition of the general arousal response in young men with psychogenic impotence and that this response declines with age.
Physiological (functional) antagonism of alpha-1 and alpha-2 adrenergic receptors activity by vasodilators: the balance between contraction and relaxation Physiological antagonism refers to the action of an agonist (e.g. PGE1, VIP or NO), which produces the opposite biological effect (relaxation) to the substance being antagonized (norepinephrine) which produces contraction. In this case, the antagonist (PGE1, VIP or NO) acts via its own receptor or enzyme and activates a signal transduction cascade that will attenuate or oppose the action of the agonist, resulting in the ®nal response observed. This concept, while de®ned in the pharmacological literature, is often not understood when several mechanisms or pathways are integrated to produce ®nal response.
Non-adrenergic non-cholinergic nerves and the vascular endothelium lining the lacunar spaces and the penile arteries release vasoactive factors that relax the trabecular smooth muscle. Nitric oxide released from the non-adrenergic non-cholinergic nerves diffuses into the smooth muscle and activates guanylyl cyclase. This results in increased synthesis of intracellular cGMP. Intracellular concentration of cGMP is regulated by cGMP-speci®c phosphodiesterases. Binding of cGMP to speci®c protein kinase G (PKG) results in its activation and phosphorylation of protein substrates leading to decreased intracellular calcium by sequestration and extrusion.
Modulation by the endothelium of agonist-induced contraction of smooth muscle by vasodilators has been recognized. 64, 65 In other vascular tissues, concentration±response curves produced by norepinephrine are displaced to the left in the absence of the endothelium, without a change in the magnitude of the maximal response. 64, 65 This suggests that norepinephrine-mediated contraction is antagonized by endothelium-derived vasoactive substances, either at the receptor level andaor at a step in the biochemical pathway leading to contraction. Contractile agonists may modulate smooth muscle relaxation by binding to a speci®c receptor on the endothelium. For instance, methoxamine, phenylephrine, clonidine and B-HT 920 (agonists that stimulate contractility in smooth muscle) increased intracellular cGMP only in the presence but not in the absence of the endothelium, suggesting release of NO, presumably via alpha-2 adrenergic receptors on the endothelium. 64 Microvascular constriction caused by alpha-1 and alpha-2 adrenergic receptor activation is signi®cantly modulated by endothelium.
Increased activation of endothelial or neural nitric oxide synthase physiologically antagonizes alpha adrenergic receptors action by synthesis and release of NO. In addition to activation of guanylyl cyclase, NO may also activate K channels or Na aK ATPase and reduces [Ca 2 ] i . 94, 95 Further, the endothelium releases vasoactive substances such as prostaglandins, which activate speci®c G s -protein-coupled receptors on the smooth muscle and increase cAMP synthesis. VIP released from the VIPergic nerves interacts with G s -protein coupled receptors and results in activation of adenylyl cyclases and increased intracellular cAMP synthesis. The signal transduction pathway of the NOacGMP via PKG counteract and overcomes the signal transduction pathway of norepinephrine mediated increase in IP3 turnover and increased intracellular calcium. This shift in the balance towards reduced intracellular calcium results in reduced contractility and enhanced relaxation. Increased intracellular levels of cAMP and cGMP result in activation of cGMP and cAMPdependent protein kinases, activation of K channels and hyperpolarization. Hyperpolarization decreases Ca 2 in¯ux through L-type Ca 2 channels thus decreasing intracellular calcium and causing smooth muscle relaxation.
Since the alpha adrenergic pathway exerts a dominant regulatory effect on trabecular smooth muscle tone, any physiological perturbations in this pathway, regardless of the nature of the mediator, may have profound in¯uence on smooth muscle contractility. An important concept to emphasize regarding the interaction of multiple and overlapping regulatory mechanisms is that no single pathway is completely inactive at any given time and is always operative at some basal level. This is illustrated by the ability of phosphodiesterase inhibitors to elevate intracellular levels of cyclic . Similarly, contraction is enhanced when basal release of NO synthesis is inhibited by arginine analogs (L-NMMA) in the presence of exogenous adrenergic agonist, suggesting that such pathways are always active at some basal level. Therefore, it is important to appreciate the contributions of the contractile and vasodilator effector systems on smooth muscle contractility. This requires a comprehensive approach to understand the potential interactions (synergistic or antagonistic) of these vasodilator and vasoconstrictor systems in the physiology of erectile function.
Future research directions
The current conceptual framework of penile erection, is that the state of penile trabecular smooth muscle tone depends on the balance and integration of signals derived from the biochemical pathways regulating smooth muscle contraction and relaxation. In thē accid state, functional synergism between the adrenergic system and other vasoconstrictors (such as endothelins, angiotension, and prostanoids), maintains contractility. Subsequent to sexual stimulation, activation of the physiological mechanisms mediating relaxation antagonizes alpha adrenergic receptor function and modi®es alpha-adrenergic receptor signaling pathway either at the receptor level andaor at one or more key steps in the cascade of [Ca 2 ] i homeostasis. Better understanding of the biochemical and physiological mechanisms modulating this functional antagonism should lead to the development of better strategies for the management of erectile dysfunction with potential use of alpha-blockers.
While several studies have reported on the expression, identi®cation and function of alpha adrenergic receptors and their subtypes in erectile tissue, 16, 17, 55, 56 no studies have addressed the following questions. What are the cellular distribution of the alpha-1 and alpha-2 adrenergic receptor subtypes on the trabecular and penile arterial smooth muscle in erectile tissue? Are alpha-1 and alpha-2 adrenergic receptor subtypes expressed with similar densities on the trabecular smooth muscle? What is the relative contribution of the various alpha adrenergic receptor subtypes to the contractile response? What are the key biochemical reactions by which the vasodilators functionally antagonize the activity of the alpha adrenergic receptor at the second messenger level? What are the basis of functional selectivity and how such information may be utilized to improve the effectiveness of alpha-blockers?
Future research will have to address many of these questions in order to broaden our understanding of the role of alpha adrenergic receptor function in modulating trabecular smooth muscle tone and penile erection. With the advent of biochemical and molecular biological approaches coupled with pharmacological and histological methods, it is possible to address these questions and delineate the molecular mechanism of alpha adrenergic function in penile erection. Investigation of the signal transduction pathways that maintain the delicate balance between vaosactive factors regulating trabecular smooth muscle contraction and relaxation, in normal erectile function, is necessary. Such research should provide better understanding of the pathophysiological mechanisms disrupting this delicate balance in aging and in diseases causing erectile dysfunction.
